eligibility_summary
Age 17–79 with advanced HCC (AASLD or path confirmed), progressed/intolerant to prior systemic therapy (TKI/ICI/chemo/VEGF), ≥2-week washout, AEs ≤G1, Child-Pugh A or B≤7, BCLC B/C or CNLC III, measurable disease (mRECIST), adequate organs, HBV/HCV controlled, ECOG 0–1, survival ≥12 wks, contraception, tumor CD20+ scattered. Exclude non-HCC histologies, encephalopathy, bleeding risk/varices, unstable brain mets, active infection (HIV/TB), recent major surgery, uncontrolled cancers, severe mAb allergy, pregnancy/lactation.
trial_source
clinical_trials.gov from Dec 2, 2025
annotation_status
ai
ai_summary
Phase 2, single-arm trial in advanced HCC adds rituximab to prior first-line PD-1/PD-L1 inhibitor plus VEGFR‑targeted therapy after progression or intolerance. Interventions/mechanisms: • Rituximab: chimeric anti‑CD20 IgG1 monoclonal antibody, depletes CD20+ B cells via ADCC/CDC/apoptosis, aiming to remodel the immunosuppressive tumor microenvironment. • PD‑1/PD‑L1 inhibitors: monoclonal antibodies that block the PD‑1/PD‑L1 checkpoint to restore exhausted T‑cell function. • VEGF/VEGFR‑targeted drugs: VEGFR tyrosine kinase inhibitors or anti‑VEGF monoclonal antibodies that inhibit angiogenesis and VEGF‑driven immunosuppression. Targets: CD20+ B cells (intratumoral, scattered, CD20 positivity required for enrollment), PD‑1/PD‑L1 axis on T cells/tumor microenvironment, and VEGF/VEGFR signaling on endothelial/tumor stromal cells.